BioSpace News Archive

SpringWorks Therapeutics, Inc. announced the pricing of its initial public offering of 9,000,000 shares of its common stock at a price to the public of $18.00 per share.

The Janssen Pharmaceutical Companies of Johnson & Johnson announced results from the randomized Phase 2 GRIFFIN (MMY2004) study showing that the addition of DARZALEX® (daratumumab) to bortezomib, lenalidomide and dexamethasone (VRd) induced higher response rates in newly diagnosed patients with multiple myeloma who were eligible for high-dose therapy and autologous stem cell transplantation (ASCT) compared with VRd alone.

Oncopeptides AB announced updated interim efficacy and safety data from the ongoing pivotal Phase 2 study, HORIZON, at the 17th International Myeloma Workshop meeting in Boston, Massachusetts, USA.

Late-breaking results support Kodiak’s objective of every three-, four-, and five-month long-interval dosing of KSI-301 in patients with wet AMD

TAE Life Sciences announced the formation of a Scientific Advisory Board to facilitate groundbreaking advancements in the emerging field of accelerator-based boron-neutron capture therapy.

Info-Tech Research Group, which launched operations in Australia and New Zealand in early 2019 with a new office opening in Sydney, has announced an exceptional start, with the launch of multiple client engagements and new member acquisitions in the region.

While current migraine treatments have limited effectiveness, and can have side effects or be unpleasant to use, Nocira® is harnessing the unique pressure-responsive neuroanatomy of the ear as a potential new frontier for rapid, effective relief via a safe, comfortable and pleasurable therapy

Strengthening its leadership in delivering innovative new solutions to transform cancer care globally, Varian announced Ethos™ therapy, an Adaptive Intelligence™ solution.

Purdue Pharma L.P. announced that it has reached an agreement in principle on a framework for settling the U.S. opioid litigation facing the Company with 24 state attorneys general, analogous officials from 5 U.S. territories, the Plaintiffs’ Executive Committee in the multidistrict litigation, and co-lead counsel in the MDL.